JP2003516936A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516936A5
JP2003516936A5 JP2001534412A JP2001534412A JP2003516936A5 JP 2003516936 A5 JP2003516936 A5 JP 2003516936A5 JP 2001534412 A JP2001534412 A JP 2001534412A JP 2001534412 A JP2001534412 A JP 2001534412A JP 2003516936 A5 JP2003516936 A5 JP 2003516936A5
Authority
JP
Japan
Prior art keywords
particles
adjuvant
antigen
coated
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516936A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/025854 external-priority patent/WO2001032208A1/en
Publication of JP2003516936A publication Critical patent/JP2003516936A/ja
Publication of JP2003516936A5 publication Critical patent/JP2003516936A5/ja
Pending legal-status Critical Current

Links

JP2001534412A 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン Pending JP2003516936A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/025854 WO2001032208A1 (en) 1999-11-03 1999-11-03 Adjuvanted genetic vaccines

Publications (2)

Publication Number Publication Date
JP2003516936A JP2003516936A (ja) 2003-05-20
JP2003516936A5 true JP2003516936A5 (https=) 2006-12-28

Family

ID=22273970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534412A Pending JP2003516936A (ja) 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン

Country Status (14)

Country Link
EP (1) EP1227840B1 (https=)
JP (1) JP2003516936A (https=)
CN (1) CN100333794C (https=)
AT (1) ATE374622T1 (https=)
AU (1) AU780448C (https=)
CA (1) CA2389686A1 (https=)
CY (1) CY1107845T1 (https=)
DE (1) DE69937258T2 (https=)
DK (1) DK1227840T3 (https=)
ES (2) ES2340617T3 (https=)
IL (2) IL149415A0 (https=)
NZ (1) NZ518766A (https=)
PT (2) PT1913957E (https=)
WO (1) WO2001032208A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1227840T1 (sl) * 1999-11-03 2008-02-29 Powderject Vaccines Inc Genetske vakcine z adjuvansom
JP2004535799A (ja) * 2001-05-18 2004-12-02 パウダージェクト ワクチンズ，インコーポレーテッド ワクチン組成物
US7566478B2 (en) 2001-07-25 2009-07-28 Nantero, Inc. Methods of making carbon nanotube films, layers, fabrics, ribbons, elements and articles
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
WO2014145906A2 (en) * 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
US11771761B2 (en) 2019-06-12 2023-10-03 Wisconsin Alumni Research Foundation Adjuvant for animal and human vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
CA2158733C (en) * 1994-01-21 2007-01-16 Dennis E. Mccabe Gas driven gene delivery instrument
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69738597T2 (de) * 1996-02-09 2008-07-24 Glaxosmithkline Biologicals S.A. Vakzine gegen das varicella zostervirus produkt von gen 63
EP1017283B1 (en) * 1997-02-14 2004-12-15 Merck & Co., Inc. Polynucleotide vaccine formulations
WO1998046263A1 (en) * 1997-04-14 1998-10-22 University Of Massachusetts Medical Center Saponin adjuvants in combination with dna vaccination
NZ504894A (en) * 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
CU22740A1 (es) * 1998-09-07 2002-02-28 Ct Ingenieria Genetica Biotech Formulación de ácidos nucleicos y acemanano

Similar Documents

Publication Publication Date Title
EP1322287B1 (en) Microparticles for delivery of the heterologous nucleic acids
JP2025063030A5 (https=)
Saroja et al. Recent trends in vaccine delivery systems: a review
O'Hagan et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
O’Hagan et al. Microparticle-based technologies for vaccines
Moser et al. Virosomal adjuvanted antigen delivery systems
Kaurav et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage
CN104027324B (zh) 一种可溶性微针疫苗贴片及其制备方法
JP4601168B2 (ja) 吸着表面を有する微小粒子、それを作製する方法、およびその使用
EP2269642A2 (en) Hcv vaccine compositions
JP2001523729A5 (https=)
Cui et al. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses
JPH11500443A (ja) コクリエート送達ビヒクル
JP2001524533A (ja) 粒子状ワクチン組成物の経皮的送達
JP2003520824A (ja) 免疫変調用医薬組成物並びに抗原および免疫原性オリゴデオキシヌクレオチドおよびアジュバントとしてのポリカチオン性ポリマーを含むワクチンの調製
JP2003514872A5 (https=)
Wang et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice
Newman et al. Immunological and formulation design considerations for subunit vaccines
JP2004508065A5 (https=)
Engler et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates
Prashant et al. Nanoparticle based tailoring of adjuvant function: the role in vaccine development
CN117298264A (zh) 基于流感病毒ha蛋白和新冠病毒s蛋白的组合物和疫苗
JP2006502228A5 (https=)
Ha et al. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination
JP2003516936A5 (https=)